Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
Wednesday, December 19, 2012, 12:00:00 PM
Condition: Hepatitis C Virus (HCV)
Interventions: Biological: Peginterferon Lambda-1a; Drug: Ribavirin; Biological: Peginterferon alfa-2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified December 2012
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
Wednesday, December 19, 2012, 12:00:00 PM
Condition: Hepatitis C
Interventions: Drug: boceprevir; Biological: PegIFN-2b; Drug: RBV
Sponsors: Merck; Merck
Not yet recruiting - verified December 2012
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
Thursday, December 13, 2012, 12:00:00 PM
Condition: Chronic Hepatitis C (CHC)
Interventions: Drug: MP-424; Drug: RBV; Drug: PEG-IFN alfa-2a
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified December 2012
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
Thursday, December 13, 2012, 12:00:00 PM
Condition: Chronic Hepatitis C(CHC)
Interventions: Drug: MP-424; Drug: RBV; Drug: IFN beta
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; Toray Industries, Inc
Recruiting - verified December 2012
An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1
Wednesday, December 12, 2012, 12:00:00 PM
Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified December 2012
A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis
Tuesday, December 11, 2012, 12:00:00 PM
Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir + ritonavir; Drug: danoprevir + ritonavir; Drug: peginterferon alfa-2a [Pegasys]; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: ribavirin [Copegus]
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified December 2012
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Mild or Moderate Hemophilia
Monday, December 03, 2012, 12:00:00 PM
Condition: Hepatitis C Virus
Interventions: Biological: Pegylated-Interferon-lambda; Drug: Ribavirin; Drug: Daclatasvir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified December 2012
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
Friday, November 30, 2012, 12:00:00 PM
Conditions: Hepatitis; Hepatitis C
Interventions: Drug: Algeron; Drug: PegIntron
Sponsors: Biocad; Biocad
Active, not recruiting - verified November 2012
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
Wednesday, November 28, 2012, 12:00:00 PM
Condition: Early Chronic Hepatitis C
Intervention: Drug: TPV/PEG-IFN/RBV
Sponsors: Kirby Institute; Kirby Institute; Janssen-Cilag Ltd.
Not yet recruiting - verified December 2012
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients
Monday, November 26, 2012, 12:00:00 PM
Conditions: Hepatitis C (HCV); Acupuncture
Intervention: Device: Acupuncture
Sponsors: Ziv Hospital; Assy Nimer
Not yet recruiting - verified December 2012
Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection
Monday, November 26, 2012, 12:00:00 PM
Condition: Chronic Hepatitis C Virus
Intervention: Drug: GS-5816
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified November 2012
A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)
Tuesday, November 20, 2012, 12:00:00 PM
Conditions: Healthy; Hepatitis C
Interventions: Drug: BMS-986094/INX-08189; Drug: Placebo matching BMS-986094/INX-08189
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2012
A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1
Monday, November 12, 2012, 12:00:00 PM
Condition: Hepatitis C Virus Genotype-1
Interventions: Drug: TMC435; Drug: Pegylated interferon alpha-2a; Drug: Ribavirin
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Active, not recruiting - verified December 2012
Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects
Saturday, November 10, 2012, 12:00:00 PM
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg; Drug: Ribavirin
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified December 2012
An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients
Friday, November 09, 2012, 12:00:00 PM
Condition: Hepatitis C, Chronic
Interventions: Drug: TMC435; Drug: Peginterferon-alpha (PegIFNα-2a); Drug: Ribavirin (RBV); Drug: Placebo
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified December 2012
IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1
Tuesday, November 06, 2012, 12:00:00 PM
Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127; Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: Ribavirin (RBV); Drug: BI 201335 (Faldaprevir); Drug: BI 201335 (Faldaprevir); Drug: BI 207127; Drug: BI 207127; Drug: Faldaprevir (BI 201335)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified December 2012
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon
Friday, November 02, 2012, 12:00:00 PM
Condition: Hepatitis C, Chronic
Interventions: Drug: BI 207127-placebo: 8-week treatment; Drug: Ribavirin: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: Faldaprevir: 24-week treatment; Drug: BI 207127: 24-week treatment; Drug: Ribavirin-placebo: 8-week treatment; Drug: Faldaprevir-placebo: 8-week treatment; Drug: Faldaprevir: 16-week treatment; Drug: Ribavirin: 16-week treatment; Drug: RBV: 24-week treatment; Drug: BI 207127: 16-week treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified December 2012
No comments:
Post a Comment